Comparison between 200 μg and 800 μg of vaginal misoprostol for cervical ripening before operative hysteroscopy: A randomized controlled trial

Objective To compare between 200 and 800 μg of vaginal misoprostol for cervical ripening before operative hysteroscopy. Methods Quadruple‐blind randomized clinical trial conducted between November 2019 and September 2020 involving 76 patients undergoing cervical dilatation before surgical hysterosco...

Full description

Saved in:
Bibliographic Details
Published in:International journal of gynecology and obstetrics 2022-07, Vol.158 (1), p.205-212
Main Authors: Maior, Maria da Conceição Farias Souto, Souza, Alex Sandro Rolland, Souza, Gustavo Fonseca de Albuquerque, Costa, Aurélio Antônio Ribeiro
Format: Article
Language:English
Subjects:
Administration, Intravaginal
Cervical Ripening
Cervix Uteri - surgery
Double-Blind Method
Female
Humans
Hysteroscopy - adverse effects
misoprostol
Misoprostol - adverse effects
operative hysteroscopy
Oxytocics - adverse effects
Pregnancy
Preoperative Care
randomized clinical trial
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To compare between 200 and 800 μg of vaginal misoprostol for cervical ripening before operative hysteroscopy. Methods Quadruple‐blind randomized clinical trial conducted between November 2019 and September 2020 involving 76 patients undergoing cervical dilatation before surgical hysteroscopy at teaching hospitals in Pernambuco, Brazil. Women received the vaginal misoprostol dosage of 200 or 800 μg,10–12 h before operative hysteroscopy. The cervical width was the primary outcome, and secondary outcomes were patient satisfaction, adverse effects, surgical complications, and duration of cervical dilatation. Chi‐square tests of association, Fisher's exact and Mann–Whitney U tests were used with an α error of
ISSN:0020-7292
1879-3479
DOI:10.1002/ijgo.13984